I-Rifampicin CAS: 13292-46-1 99% I-Orenji ukuya kumgubo obomvu / omdaka
| Inombolo Yekhathalogu | XD90358 |
| Igama lemveliso | Rifampicin |
| CAS | 13292-46-1 |
| Ifomula yeemolekyuli | I-C43H58N4O12 |
| Ubunzima beMolekyuli | 822.94 |
| Iinkcukacha zokuGcina | -15 ukuya -20 °C |
| IKhowudi yoMrhumo eHarmonized | 29419000 |
Ukucaciswa kweMveliso
| pH | 4.5-6.5 |
| Isivavanyi | 99% |
| Imbonakalo | I-Orenji ukuya kumgubo obomvu/omdaka |
| Ilahleko ekomisweni | ubuninzi 1.0% |
| Uthuthu lweSulfate | ubuninzi 1.0% |
Ukuphanda kunye nokuthelekisa ukubonakaliswa kwe-recA kunye ne-recX, amacandelo endlela ye-SOS, kulandela unyango lwe-rifampicin ekuchaphazelekeni ngamachiza kunye ne-MDR yonyango lwezifo ze-Mycobacterium tuberculosis.Strains (M. tuberculosis kunye ne-Mycobacterium smegmatis) ziye zaphantsi kwe-rifampicin- kunye ne-mitomycin-induced uxinzelelo lwe-36 h lulandelwa yi-RNA extraction.I-recA kunye ne-recX kwisicatshulwa se-RNA ziye zaqikelelwa kusetyenziswa i-qRT-PCR. Uxinzelelo lwekliniki lwe-MDR lwenziwe ngokukhawuleza (24 h) nangaphezulu (7-fold) amanqanaba e-recA xa kuthelekiswa noxinzelelo oluchaphazeleka ngamachiza (36 h) ekuphenduleni i-rifampicin. .amanqanaba e-recX afunyaniswa enyuka ngokunyuka kwamanqanaba e-recA;nangona kunjalo, amanqanaba ayephezulu kune-recA.Drug-susceptible kunye ne-MDR strains zine-kinetics ezahlukeneyo zokungeniswa kokulungiswa kwe-DNA.© The Author 2014. Ipapashwe yi-Oxford University Press egameni leBritish Society for Antimicrobial Chemotherapy.
